| Literature DB >> 26131383 |
Marjan Alimi1, Benjamin Shin1, Michael Macielak1, Christoph P Hofstetter1, Innocent Njoku1, Apostolos J Tsiouris2, Eric Elowitz1, Roger Härtl1.
Abstract
Study Design Retrospective case series. Objective StaXx XD (Spine Wave, Inc., Shelton, CT, United States) is an expandable polyaryl-ether-ether-ketone (PEEK) wafer implant utilized in the treatment of lumbar degenerative disease. PEEK implants have been successfully used as interbody devices. Few studies have focused on expandable PEEK devices. The aim of the current study is to determine the radiographic and clinical outcome of expandable PEEK cages utilized for transforaminal lumbar interbody fusion in patients with lumbar degenerative diseases. Methods Forty-nine patients who underwent lumbar interbody fusion with implantation of expandable PEEK cages and posterior instrumentation were included. The clinical outcome was evaluated using the visual analog scale (VAS) and the Oswestry Disability Index (ODI). Radiographic parameters including disk height, foraminal height, listhesis, local disk angle of the index level/levels, regional lumbar lordosis, and graft subsidence were measured preoperatively, postoperatively, and at latest follow-up. Results At an average follow-up of 19.3 months, the minimum clinically important difference for the ODI and VAS back, buttock, and leg were achieved in 64, 52, 58, and 52% of the patients, respectively. There was statistically significant improvement in VAS back (6.42 versus 3.11, p < 0.001), VAS buttock (4.66 versus 1.97, p = 0.002), VAS leg (4.55 versus 1.96, p < 0.001), and ODI (21.7 versus 12.1, p < 0.001) scores. There was a significant increase in the average disk height (6.49 versus 8.18 mm, p = 0.037) and foraminal height (15.6 versus 18.53 mm, p = 0.0001), and a significant reduction in the listhesis (5.13 versus 3.15 mm, p = 0.005). The subsidence of 0.66 mm (7.4%) observed at the latest follow-up was not significant (p = 0.35). Conclusions Midterm results indicate that expandable PEEK spacers can effectively and durably restore disk and foraminal height and improve the outcome without significant subsidence.Entities:
Keywords: Oswestry Disability Index; disc height; expandable PEEK cage; graft subsidence; interbody fusion; lumbar lordosis; lumbar spine; visual analog scale
Year: 2015 PMID: 26131383 PMCID: PMC4472284 DOI: 10.1055/s-0035-1552988
Source DB: PubMed Journal: Global Spine J ISSN: 2192-5682
Fig. 1Example distraction of L5–S1 disk space resulting from in situ expansion of an interbody cage. Top left: L5–S1 disk space prior to surgery. Top right: Implantation of the expandable polyaryl-ether-ether-ketone (PEEK) spacer prior to expansion. Bottom left: In situ expansion of the PEEK spacer. Bottom right: The end of the operation.
Fig. 2Examples of radiologic outcome measurements. (A) Anterior and posterior disk heights. (B) Foraminal height. (C) Listhesis. (D) Regional lumbar lordosis (the top and the bottom most lines) and the local disk angle at the index level/levels (the pair of lines located in the middle).
Patient demographics (n = 49)
| Variable |
|
|---|---|
| Age | 59.6 ± 15.46 |
| Gender (M/F) | 21/28 |
| BMI | 28.7 ± 7.25 |
| Current smoker | 12 (24.4%) |
| Diabetic | 6 (12.2%) |
| Current steroid medication user | 2 (4.1%) |
| Previous surgery at index level | 14 (28.6%) |
| At an outside center | 7 (14.3%) |
| At our own center | 5 (10.2%) |
| At both outside and our own center | 2 (4.1%) |
| Preoperative diagnosis | |
| Spondylolisthesis | 29 (59.1%) |
| Degenerative disk disease | 14 (28.6%) |
| Previous nonunion/pseudarthrosis | 5 (10.2%) |
| Post laminectomy syndrome | 4 (8.1%) |
| Instrumentation/mechanical failure | 6 (12.2%) |
| Scoliosis | 1 (2%) |
| Trauma | 1 (2%) |
Abbreviations: BMI, body mass index; SD, standard deviation.
Operative data
| Variable |
|
|---|---|
| Total number of operated levels | 62 |
| Fusion level | |
| T12–L1 | 2 (3.3%) |
| L1–L2 | 3 (4.8%) |
| L2–L3 | 3 (4.8%) |
| L3–L4 | 8 (12.9%) |
| L4–L5 | 26 (41.9%) |
| L5–S1 | 20 (32.3%) |
| PEEK cage as part of single level MIS TLIF | 36 (73.5%) |
| PEEK cage(s) as part of multilevel open surgery | 13 (26.5%) |
| Unilateral cage | 83.7% |
| Bilateral cages | 16.3% |
| Final cage height (mm) | 10.9 ± 0.99 |
| Graft substance used for fusion | |
| Si-CaP only | 61.7% |
| Si-CaP and bone morphogenic protein | 23.6% |
| Si-CaP and autograft/demineralized bone matrix | 14.7% |
Abbreviations: MIS, minimally invasive; PEEK, polyaryl-ether-ether-ketone; Si-CaP, silicate calcium phosphate; TLIF, transforaminal lumbar interbody fusion.
Average ± standard deviation.
Clinical outcome
| Outcome variable | Preoperative | Latest follow-up |
|
|---|---|---|---|
| VAS back | 6.4 ± 0.6 | 3.1 ± 0.6 | <0.001 |
| VAS buttock | 4.6 ± 0.5 | 1.9 ± 0.5 | 0.002 |
| VAS leg | 4.5 ± 0.5 | 1.9 ± 0.5 | <0.001 |
| Oswestry Disability Index | 44.0 ± 3.2 | 24.2 ± 3.8 | <0.001 |
Results are mean ± standard error.
p values <0.05 are considered to be statistically significant.
Radiographic outcome
| Variable | Preoperative | Latest follow-up |
|
|---|---|---|---|
| Disk height | 6.5 ± 0.62 | 8.2 ± 0.61 | 0.037 |
| Foraminal height | 15.6 ± 0.67 | 18.5 ± 0.57 | <0.001 |
| Listhesis | 5.1 ± 0.77 | 3.1 ± 0.36 | 0.005 |
| Local disk angle | 6.5 ± 0.85 | 8.1 ± 0.93 | 0.122 |
| Lumbar lordodsis | 45.8 ± 2.73 | 48.0 ± 2.14 | 0.248 |
Results are mean ± standard error.
p values <0.05 are considered to be statistically significant.
Subsidence
| Immediate postoperative | Latest follow-up |
| |
|---|---|---|---|
| Disk height | 8.8 ± 0.42 | 8.2 ± 0.61 | 0.351 |
Results are mean ± standard error.
Fig. 3Clinical outcomes of 40/49 patients at the latest follow-up on average 19.3 months after the surgery; Oswestry Disability Index (ODI), visual analog scale (VAS) back, VAS buttock, and VAS leg were all significantly improved. *p < 0.001; **p < 0.001; ***p = 0.002; ****p < 0.001.
Fig. 4Radiologic outcomes of 45/49 patients at the latest follow-up on average 19.3 months. Average disk height and average foraminal height were significantly improved. NS, not significant. *p = 0.026; **p = 0.0001; † p = 0.35; ***p = 0.0001.
Fig. 5Radiologic outcomes of 45/49 patients (58/62 levels) at the latest follow-up on average 19.3 months. Listhesis was significantly improved. However, the local disk angle and regional lumbar lordosis were not significantly changed. NS, not significant. † p = 0.12; †† p = 0.24; *p = 0.005.
Fusion rate
| Group of patients | No. of cases fused (%) |
|---|---|
| All patients (evaluated in 34 patients with available latest follow-up CT scans) | 17/34 (50%) |
| Patients with Si-CaP and bone morphogenic protein | 5/8 (62.5%) |
| Patients with Si-CaP and autograft and/or demineralized bone matrix | 5/5 (100%) |
Abbreviations: CT, computed tomography; Si-CaP, silicate calcium phosphate.
Complications (n = 49)
| Variable |
|
|---|---|
| Perioperative inpatient complications | |
| Dural tear | 4 (8.2%) |
| Wound infection | 2 (4.1%) |
| Reoperations at index level | 4 (8.1%) |
| Nonunion | 3 (6.1%) |
| Adjacent level disease | 1 (2.0%) |
Different expandable cages used for TLIF
| Device | Cage | Substance | Types | Height size | Footplates |
|---|---|---|---|---|---|
| StaXx XD Expandable Device (Spine Wave, Inc., Shelton, CT, United States) |
| PEEK | Convex/lordotic | Starts at 7 mm; expands in situ in 1-mm increments, up to 15 mm | Width 9 and 11 mm; length 22, 25, and 29 mm |
| CALIBER expandable lumbar fusion device (Globus Medica, Inc., Audubon, PA, United States) |
| PEEK and titanium | Parallel and lordotic options | Starts at 8 mm; expansion options from 8 to 17 mm | Width 10 and 12 mm; length 22, 26, and 30 mm |
| AccuLIF TL (CoAlign Innovations, Allendale, NJ, United States) |
| Titanium | Lordotic | Starts at 6 mm; expansion options from 6 to 16 mm | Width 11 mm; length 30 mm |
| SmArtCage-L Expandable and self-positioning interbody fusion cage dedicated to TLIF (SmartSpine SAS, Saint Victoret, France) |
| Peek-Optima (with the addition of BaSo4) | Biconvex | Starts at 7 mm; four different heights: 7, 9, 11, and 13 mm | Width 15 mm; length 30 mm |
Note: The SmArtCage-L device is currently not utilized in the U.S. practice for TLIF surgery. The device requires FDA approval. The other three devices are FDA approved.
Abbreviations: FDA, U.S. Food and Drug Administration; PEEK, polyaryl-ether-ether-ketone; TLIF, transforaminal lumbar interbody fusion.